Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to Sell at BidaskClub

BidaskClub lowered shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a hold rating to a sell rating in a research note published on Thursday, September 5th, BidAskClub reports.

AUPH has been the subject of several other research reports. HC Wainwright restated a buy rating and issued a $25.00 price target on shares of Aurinia Pharmaceuticals in a research note on Tuesday, June 4th. Royal Bank of Canada reiterated a buy rating and set a $11.00 target price on shares of Aurinia Pharmaceuticals in a research note on Thursday, August 8th. Finally, Zacks Investment Research downgraded shares of Aurinia Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $15.18.

Shares of NASDAQ AUPH traded up $0.03 during trading on Thursday, reaching $6.48. 1,648 shares of the company traded hands, compared to its average volume of 418,830. Aurinia Pharmaceuticals has a 12-month low of $5.06 and a 12-month high of $7.85. The stock has a market cap of $595.98 million, a P/E ratio of -8.51 and a beta of 1.12. The firm’s fifty day simple moving average is $5.92 and its 200 day simple moving average is $6.29.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.08% and a negative net margin of 13,231.97%. As a group, equities analysts expect that Aurinia Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AUPH. Toronto Dominion Bank raised its holdings in shares of Aurinia Pharmaceuticals by 64.7% in the first quarter. Toronto Dominion Bank now owns 9,780 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 3,842 shares during the last quarter. Redmile Group LLC purchased a new position in Aurinia Pharmaceuticals during the first quarter worth approximately $2,101,000. Deutsche Bank AG raised its stake in Aurinia Pharmaceuticals by 413.2% during the fourth quarter. Deutsche Bank AG now owns 66,200 shares of the biotechnology company’s stock worth $451,000 after purchasing an additional 53,300 shares during the period. Spark Investment Management LLC purchased a new position in Aurinia Pharmaceuticals during the first quarter worth approximately $71,000. Finally, Knott David M purchased a new position in Aurinia Pharmaceuticals during the first quarter worth approximately $343,000. Institutional investors own 31.96% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: LIBOR

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.